Last Updated : May 4, 2024
The latest CADTH Reimbursement Review reports are posted to this page. CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.
| Brand Name | Generic Name | Therapeutic Area Sort descending | Recommendation Type | Project Status | Date Submission Received | Date Recommendation Issued |
|---|---|---|---|---|---|---|
| N/A | abiraterone, prednisone, docetaxel | Metastatic castration sensitive prostate cancer (mCSPC) | Reimburse | Complete | ||
| Pluvicto | lutetium vipivotide tetraxetan | Metastatic castration-resistant prostate cancer | Reimburse with clinical criteria and/or conditions | Complete | ||
| Lynparza | olaparib | Metastatic castration-resistant prostate cancer (mCRPC) | Reimburse with clinical criteria and/or conditions | Complete | ||
| Akeega | niraparib abiraterone acetate | Metastatic castration-resistant prostate cancer (mCRPC) | Reimburse with clinical criteria and/or conditions | Complete | ||
| Talzenna | talazoparib | Metastatic castration-resistant prostate cancer (mCRPC) | Suspended | |||
| Lynparza | Olaparib | metastatic castration-resistant prostate cancer (mCRPC) | Reimburse with clinical criteria and/or conditions | Complete | ||
| Nubeqa | darolutamide | Metastatic castration-sensitive prostate cancer | Reimburse with clinical criteria and/or conditions | Complete | ||
| Erleada | Apalutamide | metastatic castration-sensitive prostate cancer (mCSPC) | Reimburse with clinical criteria and/or conditions | Complete | ||
| Lonsurf | Trifluridine and Tipiracil | Metastatic Colorectal Cancer | Do not reimburse | Complete | ||
| Braftovi | encorafenib | Metastatic colorectal cancer | Reimburse with clinical criteria and/or conditions | Complete |
Last Updated : May 4, 2024